本研究的目的是量化 2010 年至 2019 年少数族裔服务医院 (MSH) 和非 MSH 之间在乳腺癌、前列腺癌、非小细胞肺癌和结肠癌方面的癌症治疗提供差异，并评估改善少数族裔服务医院 (MSH) 和非 MSH 的护理服务的影响。 MSH 的国家差异。来自国家癌症数据库（2010-2019 年）的数据确定了有资格接受特定癌症明确治疗的患者。按少数族裔患者比例排名前十分位的医院被归类为 MSH。根据患者和医院特征调整的多变量逻辑回归比较了在 MSH 与非 MSH 接受明确治疗的几率。通过模拟来估计，如果 MSH 护理与非 MSH 护理水平相匹配，接受明确治疗的患者数量会增加。在来自 1330 家医院的 2,927,191 名患者中，9.3% 在 MSH 接受治疗。 MSH 在所有癌症类型中提供明确治疗的几率显着较低（调整后的比值比：乳腺癌，0.83；前列腺癌，0.69；非小细胞肺癌，0.73；结肠癌，0.81）。对于任何癌症来说，护理-种族相互作用的位点均不显着 (p > .05)。 MSH 的治疗率均衡可能会导致 10 年内有 5719 名额外的患者接受明确的治疗。目前的研究结果强调了 MSH 和非 MSH 在乳腺癌、前列腺癌、非小细胞肺癌和结肠癌的明确癌症治疗方面存在系统性差异。尽管有针对性地改善 MSH 是实现公平的关键一步，但这项研究强调需要进行综合性、全系统的努力，以解决种族和民族健康差异的多方面问题。加强 MSH 的护理可以作为实现所有人医疗保健公平的更广泛举措的关键战略。© 2024 美国癌症协会。

The objective of this study was to quantify disparities in cancer treatment delivery between minority-serving hospitals (MSHs) and non-MSHs for breast, prostate, nonsmall cell lung, and colon cancers from 2010 to 2019 and to estimate the impact of improving care at MSHs on national disparities.Data from the National Cancer Database (2010-2019) identified patients who were eligible for definitive treatments for the specified cancers. Hospitals in the top decile by minority patient proportion were classified as MSHs. Multivariable logistic regression adjusted for patient and hospital characteristics compared the odds of receiving definitive treatment at MSHs versus non-MSHs. A simulation was used to estimate the increase in patients receiving definitive treatment if MSH care matched the levels of non-MSH care.Of 2,927,191 patients from 1330 hospitals, 9.3% were treated at MSHs. MSHs had significant lower odds of delivering definitive therapy across all cancer types (adjusted odds ratio: breast cancer, 0.83; prostate cancer, 0.69; nonsmall cell lung cancer, 0.73; colon cancer, 0.81). No site of care-race interaction was significant for any of the cancers (p > .05). Equalizing treatment rates at MSHs could result in 5719 additional patients receiving definitive treatment over 10 years.The current findings underscore systemic disparities in definitive cancer treatment delivery between MSHs and non-MSHs for breast, prostate, nonsmall cell lung, and colon cancers. Although targeted improvements at MSHs represent a critical step toward equity, this study highlights the need for integrated, system-wide efforts to address the multifaceted nature of racial and ethnic health disparities. Enhancing care at MSHs could serve as a pivotal strategy in a broader initiative to achieve health care equity for all.© 2024 American Cancer Society.